Sinopsis
In this podcast series sponsored by Biopharmaceutical Section of American Statistical Association, key opinion leaders from pharmaceutical industry and regulatory agencies talk about upcoming statistical conferences and events, and discuss current issues in Biopharmaceutical statistics.
Episodios
-
Episode 53: Abuse Deterrent Opioids
31/05/2018 Duración: 43minLing Chen and Kunthel By discuss methods related to the development of abuse deterrent opioids.
-
Episode 52: ASA Accreditation
27/04/2018 Duración: 01h10minZoltan Harsanyi, Janet McDougall, and Theresa Utlaut discuss the PStat® and GStat® accreditations.
-
Episode 51: The Effective Statistician
28/03/2018 Duración: 46minAlexander Schacht and Benjamin Piske discuss their new podcast and the many ways statisticians can make themselves more effective.
-
Episode 50: Lisa LaVange
21/02/2018 Duración: 50minASA President Lisa LaVange describes her varied career across industry, government and academia, and discusses the establishment of the ASA Leadership Institute.
-
Episode 49: Heather Thomas
25/01/2018 Duración: 47minHeather discusses her goals for the Biopharmaceutical Section in 2018 and describes the life of a medical product statistician living in a non-traditional area.
-
Episode 48: PhUSE, the Pharmaceutical Users Software Exchange
02/12/2017 Duración: 51minStephen Bamford, Chris Hurley and James Johnson discuss the motivation for and initiatives of PhUSE
-
Episode 47: Pediatric Medical Product Development
06/11/2017 Duración: 45minSusan Wang and Amy Xia discuss the challenges of pediatric medical product development.
-
Episode 46: Re-Randomization of Subjects Scientific Working Group
15/10/2017 Duración: 53minGheorghe Doros, Anastasia Ivanova, and George Papakostas discuss the Sequential Parallel Comparison Design and the newly-formed Clinical Trial Designs with Re-Randomization of Subjects Scientific Working Group.
-
Episode 45: Kelly Zou
19/09/2017 Duración: 24minKelly shares her thoughts on real world data and real world evidence in the healthcare and pharmaceutical industry.
-
Episode 44: Weili He and Martin Ho
17/08/2017 Duración: 35minWeili and Martin discuss the 2017 Regulatory-Industry Statistics Workshop.
-
Episode 43: 40th Anniversary of PSI
27/07/2017 Duración: 47minAndy Grieve, Nigel Howitt, John Lewis and Lucy Rowell reminisce about PSI’s past and look forward to its future.
-
Episode 42: Committee on Minorities in Statistics
29/06/2017 Duración: 47minReneé Moore and Janelle Charles discuss the mission and major initiatives of the Committee on Minorities in Statistics and the many ways statisticians can get involved.
-
Episode 41: Liz Stuart
05/06/2017 Duración: 42minLiz discusses the Health Policy Statistics Section (HPSS) of the ASA, the upcoming 2018 International Conference on Health Policy Statistics (ICHPS), as well as some of the major topic areas of focus for health policy statistics.
-
Episode 40: Estimands
08/05/2017 Duración: 56minYuki Ando, Frank Bretz, Rob Hemmings and Tom Permutt discuss estimands and the ICH E9 revisions.
-
Episode 39: Alex Dmitrienko
14/03/2017 Duración: 58minAlex discusses multiplicity, the FDA’s draft guidance on multiple endpoints, and the BIOP pilot online training program.
-
Episode 38: Amanda Golbeck
20/02/2017 Duración: 33minAmanda discusses statistical leadership and her book Leadership and Women in Statistics.
-
Episode 37: Multiregional Clinical Trials
26/01/2017 Duración: 01h01minAloka Chakravarty, Laurie Letvak and Bill Wang discuss MRCTs and the draft ICH E17 guidance.
-
Episode 36: Statistical Leadership
21/12/2016 Duración: 59minSonia Davis, Bill Sollecito and Paula Brown Stafford discuss statistical leadership and leadership training at the University of North Carolina at Chapel Hill.
-
Episode 35: EFSPI Benefit-Risk Working Group
10/11/2016 Duración: 44minAlexander Schacht and Ian Hirsch discuss benefit-risk and the efforts of the EFSPI working group.
-
Episode 34: Patient Preferences in Medical Product Evaluation
07/10/2016 Duración: 45minTelba Irony and Martin Ho discuss the important of patient preferences.